Ross Martin

Infrequent Development of Resistance in Genotype 1–6 Hepatitis C Virus–Infected Subjects Treated With Sofosbuvir in Phase 2 and 3 Clinical Trials

Evguenia S. Svarovskaia, Hadas Dvory‐Sobol, Neil Parkin et al. · Clinical Infectious Diseases · 2014 · 216 citations · Full text

Life Sciences, Infectious Diseases, Pharmacotherapy +17

NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: Prevalence and effect on treatment outcome

Stefan Zeuzem, Masashi Mizokami, Stephen Pianko et al. · Journal of Hepatology · 2017 · 203 citations · Full text

Life Sciences, Genetics, Infectious Diseases +17

Contribution of a mutational bias in hepatitis C virus replication to the genetic barrier in the development of drug resistance

Megan H. Powdrill, Egor P. Tchesnokov, Robert Kozak et al. · Proceedings of the National Academy of Sciences · 2011 · 140 citations

Life Sciences, Genetics, Molecular Biology +17

Late Relapse Versus Hepatitis C Virus Reinfection in Patients With Sustained Virologic Response After Sofosbuvir-Based Therapies

Christoph Sarrazin, Evguenia S. Svarovskaia, Charlotte Hedskog et al. · Clinical Infectious Diseases · 2016 · 108 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Characterization of Hepatitis C Virus Resistance from a Multiple-Dose Clinical Trial of the Novel NS5A Inhibitor GS-5885

Kelly A. Wong, Angela Worth, Ross Martin et al. · Antimicrobial Agents and Chemotherapy · 2013 · 95 citations · Full text

Life Sciences, Infectious Diseases, Pharmacology +17